Rapid and Continued T-Cell Differentiation into Long-term Effector and Memory Stem Cells in Vaccinated Melanoma Patients

Clinical Cancer Research

Volumn 23, Issue 13, 2017, Pages 3285-3296

  Gannon, Philippe O ^a   Baumgaertner, Petra ^b   Huber, Alexandre ^a   Iancu, Emanuela M ^a   Cagnon, Laurene ^a,b   Maillard, Samia Abed ^a,b   Hajjami, Hel ene Maby El ^b   Speiser, Daniel E ^a,b   Rufer, Nathalie ^a,b  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF LAUSANNE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AGATOLIMOD; FREUND ADJUVANT; MELAN A; MONTANIDE ISA 51; CANCER VACCINE; HLA A2 ANTIGEN; INCOMPLETE FREUND'S ADJUVANT; LIPID; MLANA PROTEIN, HUMAN; TUMOR ANTIGEN;

ARTICLE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; COHORT ANALYSIS; DRUG SAFETY; DRUG TOLERABILITY; EFFECTOR CELL; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENETIC TRANSCRIPTION; GRANULOMA; HUMAN; HUMAN CELL; INJECTION SITE REACTION; LOW DRUG DOSE; LYMPHOCYTE DIFFERENTIATION; MELANOMA; MEMORY CELL; PRIORITY JOURNAL; STAINING; STEM CELL; STEM CELL EXPANSION; T LYMPHOCYTE; VACCINATION; ADOPTIVE TRANSFER; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY;

ADOPTIVE TRANSFER; ANTIGENS, NEOPLASM; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FREUND'S ADJUVANT; HLA-A2 ANTIGEN; HUMANS; IMMUNOLOGIC MEMORY; LIPIDS; LYMPHOCYTE ACTIVATION; MART-1 ANTIGEN; MELANOMA; STEM CELLS; T-LYMPHOCYTES;

EID: 85021747279     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-16-1708     Document Type: Article

References (40)

1. Speiser DE, Romero P. Molecularly defined vaccines for cancer immunotherapy, and protective T cell immunity. Semin Immunol 2010;22:144–54.
2. Melero I, Gaudernack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for cancer: an overview of clinical trials. Nat Rev Clin Oncol 2014;11:509–24.
3. Rosenberg SA, Dudley ME, Restifo NP. Cancer immunotherapy. N Engl J Med 2008;359:1072.
4. Lee KH, Wang E, Nielsen MB, Wunderlich J, Migueles S, Connors M, et al. Increased vaccine-specific T cell frequency after peptide-based vaccination correlates with increased susceptibility to in vitro stimulation but does not lead to tumor regression. J Immunol 1999;163:6292–300.
5. Walker EB, Haley D, Miller W, Floyd K, Wisner KP, Sanjuan N, et al. gp100 (209-2M) peptide immunization of human lymphocyte antigen-A2þ stage I-III melanoma patients induces significant increase in antigen-specific effector and long-term memory CD8þ T cells. Clin Cancer Res 2004;10: 668–80.
6. Rosenberg SA, Sherry RM, Morton KE, Scharfman WJ, Yang JC, Topalian SL, et al. Tumor progression can occur despite the induction of very high levels of self/tumor antigen-specific CD8þ T cells in patients with melanoma. J Immunol 2005;175:6169–76.
7. Walker EB, Haley D, Petrausch U, Floyd K, Miller W, Sanjuan N, et al. Phenotype and functional characterization of long-term gp100-specific memory CD8þ T cells in disease-free melanoma patients before and after boosting immunization. Clin Cancer Res 2008;14:5270–83.
8. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med 2011;364:2119–27.
9. Cormier JN, Salgaller ML, Prevette T, Barracchini KC, Rivoltini L, Restifo NP, et al. Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am 1997;3:37–44.
10. Wang F, Bade E, Kuniyoshi C, Spears L, Jeffery G, Marty V, et al. Phase I trial of a MART-1 peptide vaccine with incomplete Freund's adjuvant for resected high-risk melanoma. Clin Cancer Res 1999;5:2756–65.
11. Aucouturier J, Dupuis L, Deville S, Ascarateil S, Ganne V. Montanide ISA 720 and 51: a new generation of water in oil emulsions as adjuvants for human vaccines. Expert Rev Vaccines 2002;1:111–8.
12. Lienard D, Rimoldi D, Marchand M, Dietrich PY, van Baren N, Geldhof C, et al. Ex vivo detectable activation of Melan-A-specific T cells correlating with inflammatory skin reactions in melanoma patients vaccinated with peptides in IFA. Cancer Immun 2004;4:4.
13. Klinman DM. Immunotherapeutic uses of CPG oligodeoxynucleotides. Nat Rev Immunol 2004;4:249–58.
14. Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov 2006;5:471–84.
15. Speiser DE, Lienard D, Rufer N, Rubio-Godoy V, Rimoldi D, Lejeune F, et al. Rapid and strong human CD8þ T cell responses to vaccination with peptide, IFA, and CPG oligodeoxynucleotide 7909. J Clin Invest 2005;115: 739–46.
16. Karbach J, Gnjatic S, Bender A, Neumann A, Weidmann E, Yuan J, et al. Tumor-reactive CD8þ T-cell responses after vaccination with NY-ESO-1 peptide, CPG 7909 and Montanide ISA-51: association with survival. Int J Cancer 2010;126:909–18.
17. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011;17: 1290–7.
18. Lugli E, Dominguez MH, Gattinoni L, Chattopadhyay PK, Bolton DL, Song K, et al. Superior T memory stem cell persistence supports long-lived T cell memory. J Clin Invest 2013;123:594–9.
19. Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, et al. Wnt signalingarrestseffectorTcelldifferentiationandgeneratesCD8þmemory stem cells. Nat Med 2009;15:808–13.
20. Vigano S, Negron J, Ouyang Z, Rosenberg ES, Walker BD, Lichterfeld M, et al. Prolonged antiretroviral therapy preserves HIV-1-specific CD8 T cells with stem cell-like properties. J Virol 2015;89:7829–40.
21. Ahmed R, Akondy RS. Insights into human CD8(þ) T-cell memory using the yellow fever and smallpox vaccines. Immunol Cell Biol 2011;89: 340–5.
22. Baumgaertner P, Jandus C, Rivals JP, Derre L, Lovgren T, Baitsch L, et al. Vaccination-induced functional competence of circulating human tumor-specific CD8 T-cells. Int J Cancer 2012;130:2607–17.
23. Speiser DE, Baumgaertner P, Voelter V, Devevre E, Barbey C, Rufer N, et al. Unmodified self antigen triggers human CD8 T cells with stronger tumor reactivity than altered antigen. Proc Natl Acad Sci U S A 2008;105:3849–54.
24. Speiser DE, Wieckowski S, Gupta B, Iancu EM, Baumgaertner P, Baitsch L, et al. Single cell analysis reveals similar functional competence of dominant and nondominant CD8 T-cell clonotypes. Proc Natl Acad Sci U S A 2011;108:15318–23.
25. Gupta B, Iancu EM, Gannon PO, Wieckowski S, Baitsch L, Speiser DE, et al. Simultaneous coexpression of memory-related and effector-related genes by individual human CD8 T cells depends on antigen specificity and differentiation. J Immunother 2012;35:488–501.
26. Gannon PO, Wieckowski S, Baumgaertner P, Hebeisen M, Allard M, Speiser DE, et al. Quantitative TCR:pMHC dissociation rate assessment by NTAmers reveals antimelanoma T cell repertoires enriched for high functional competence. J Immunol 2015;195:356–66.
27. Wieckowski S, Baumgaertner P, Corthesy P, Voelter V, Romero P, Speiser DE, et al. Fine structural variations of alphabetaTCRs selected by vaccination with natural versus altered self-antigen in melanoma patients. J Immunol 2009;183:5397–406.
28. Lefranc MP. Nomenclature of the human T cell receptor genes. Curr Protoc Immunol 2001;Appendix 1:Appendix 1O.
29. Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, et al. Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells. Nat Protoc 2013;8:33–42.
30. Perret R, Sierro SR, Botelho NK, Corgnac S, Donda A, Romero P. Adjuvants that improve the ratio of antigen-specific effector to regulatory T cells enhance tumor immunity. Cancer Res 2013;73:6597–608.
31. Le Gal FA, Widmer VM, Dutoit V, Rubio-Godoy V, Schrenzel J, Walker PR, et al. Tissue homing and persistence of defined antigen-specific CD8þ tumor-reactive T-cell clones in long-term melanoma survivors. J Invest Dermatol 2007;127:622–9.
32. Derre L, Bruyninx M, Baumgaertner P, Devevre E, Corthesy P, Touvrey C, et al. In vivo persistence of codominant human CD8þ T cell clonotypes is not limited by replicative senescence or functional alteration. J Immunol 2007;179:2368–79.
33. Speiser DE, Baumgaertner P, Barbey C, Rubio-Godoy V, Moulin A, Corthesy P, et al. A novel approach to characterize clonality and differentiation of human melanoma-specific T cell responses: spontaneous priming and efficient boosting by vaccination. J Immunol 2006;177:1338–48.
34. Robbins PF, Dudley ME, Wunderlich J, El-Gamil M, Li YF, Zhou J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol 2004;173:7125–30.
35. Butler MO, Friedlander P, Milstein MI, Mooney MM, Metzler G, Murray AP, et al. Establishment of antitumor memory in humans using in vitro-educated CD8þ T cells. Sci Transl Med 2011;3:80ra34.
36. Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, et al. Transferred melanoma-specific CD8þ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A 2012;109:4592–7.
37. Tanaka Y, Nakasone H, Yamazaki R, Wada H, Ishihara Y, Kawamura K, et al. Long-term persistence of limited HTLV-I Tax-specific cytotoxic T cell clones in a patient with adult T cell leukemia/lymphoma after allogeneic stem cell transplantation. J Clin Immunol 2012;32: 1340–52.
38. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. Blood 2014;124:453–62.
39. Hebeisen M, Schmidt J, Guillaume P, Baumgaertner P, Speiser DE, Luescher I, et al. Identification of rare high-avidity, tumor-reactive CD8þ T cells by monomeric TCR-ligand off-rates measurements on living cells. Cancer Res 2015;75:1983–91.
40. Mahnke YD, Brodie TM, Sallusto F, Roederer M, Lugli E. The who's who of T-cell differentiation: human memory T-cell subsets. Eur J Immunol 2013;43:2797–809.